ZHX2 could also downregulate the expression of multiple drug resistance gene at the transcriptional level to enhance the susceptibilities of tumor cells to chemotherapy drugs in hepatocellular cancer [22] and myeloma [23]; however, the deficiency of von Hippel–Lindau could upregulate the expression of ZHX2 and result in increased binding between ZHX2 and H2K4me3, which activates the nuclear factor‐kappa B pathway in renal clear cell carcinoma [12]. The gene discussed is ZHX2; the disease is plasma cell myeloma.